Amendments

In the Claims:

Please cancel claims 41-73 without prejudice to or disclaimer of the subject matter therein.

Please add the following new claims:

-- 74. An isolated nucleic acid molecule comprising a polynucleotide encoding a mature portion of a protein consisting of SEQ ID NO:2.

75. An isolated nucleic acid molecule comprising a polynucleotide encoding a mature portion of a protein as encoded by the vascular endothelial growth factor-3 (VEGF-3) cDNA clone contained in ATCC Deposit No. 97116.

76. An isolated nucleic acid molecule comprising a polynucleotide encoding a polypeptide of amino acids 69 to 82 of SEQ ID NO:2 and of at least 50 contiguous amino acids of SEQ ID NO:2.

77. The isolated nucleic acid molecule of claim 76, wherein said polypeptide comprises amino acids 46 to 123 of SEQ ID NO:2.

78. The isolated nucleic acid molecule of claim 77, wherein said polypeptide comprises amino acids 30 to 221 of SEQ ID NO:2.

79. The isolated nucleic acid molecule of claim 76, comprising nucleotides 205 to 246 of SEQ ID NO:1.

80. The isolated nucleic acid molecule of claim 77, comprising nucleotides 136 to 369 of SEQ ID NO:1.

81. The isolated nucleic acid molecule of claim 78, comprising nucleotides 88 to 663 of SEQ ID NO:1.

82. The isolated nucleic acid molecule of claim 74, wherein said polynucleotide is fused to a heterologous polynucleotide.

83. The isolated nucleic acid molecule of claim 75, wherein said polynucleotide is fused to a heterologous polynucleotide.

E cont

84. The isolated nucleic acid molecule of claim 76, wherein said polynucleotide is fused to a heterologous polynucleotide.

85. The isolated nucleic acid molecule of claim 77, wherein said polynucleotide is fused to a heterologous polynucleotide.

86. The isolated nucleic acid molecule of claim 78, wherein said polynucleotide is fused to a heterologous polynucleotide.

87. The isolated nucleic acid molecule of claim 82, wherein said heterologous polynucleotide encodes a heterologous polypeptide.

88. The isolated nucleic acid molecule of claim 83, wherein said heterologous polynucleotide encodes a heterologous polypeptide.

89. The isolated nucleic acid molecule of claim 84, wherein said heterologous polynucleotide encodes a heterologous polypeptide.

90. The isolated nucleic acid molecule of claim 85, wherein said heterologous polynucleotide encodes a heterologous polypeptide.

91. The isolated nucleic acid molecule of claim 86, wherein said heterologous polynucleotide encodes a heterologous polypeptide.

92. A recombinant vector comprising the isolated nucleic acid molecule of claim 74.

93. A recombinant vector comprising the isolated nucleic acid molecule of claim 75.

94. A recombinant vector comprising the isolated nucleic acid molecule of claim 76.

95. A recombinant vector comprising the isolated nucleic acid molecule of claim 77.

96. A recombinant vector comprising the isolated nucleic acid molecule of claim 78.

97. The recombinant vector of claim 92, wherein said isolated nucleic acid molecule is operatively associated with a regulatory sequence that controls gene expression.

98. The recombinant vector of claim 93, wherein said isolated nucleic acid molecule is operatively associated with a regulatory sequence that controls gene expression.

99. The recombinant vector of claim 94, wherein said isolated nucleic acid molecule is operatively associated with a regulatory sequence that controls gene expression.

100. The recombinant vector of claim 95, wherein said isolated nucleic acid molecule is operatively associated with a regulatory sequence that controls gene expression.

101. The recombinant vector of claim 96, wherein said isolated nucleic acid molecule is operatively associated with a regulatory sequence that controls gene expression.

E1 Cont.

102. A genetically engineered host cell comprising the isolated nucleic acid molecule of claim 74.

103 A genetically engineered host cell comprising the isolated nucleic acid molecule of claim 75.

104. A genetically engineered host cell comprising the isolated nucleic acid molecule of claim 76.

105. A genetically engineered host cell comprising the isolated nucleic acid molecule of claim 77.

106. A genetically engineered host cell comprising the isolated nucleic acid molecule of claim 78.

107. The genetically engineered host cell of claim 102, wherein said polynucleotide is operatively associated with a regulatory sequence that controls gene expression.

108. The genetically engineered host cell of claim 103, wherein said polynucleotide is operatively associated with a regulatory sequence that controls gene expression.

E1 cont.

109. The genetically engineered host cell of claim 104, wherein said polynucleotide is operatively associated with a regulatory sequence that controls gene expression.

110. The genetically engineered host cell of claim 105, wherein said polynucleotide is operatively associated with a regulatory sequence that controls gene expression.

111. The genetically engineered host cell of claim 106, wherein said polynucleotide is operatively associated with a regulatory sequence that controls gene expression.

112. A method for producing a VEGF-3 polypeptide, comprising:

(a) culturing the genetically engineered host cell of claim 107 under conditions suitable to produce the polypeptide; and

(b) recovering the polypeptide from the cell culture.

113. A method for producing a VEGF-3 polypeptide, comprising:

(a) culturing the genetically engineered host cell of claim 108 under conditions suitable to produce the polypeptide; and

(b) recovering the polypeptide from the cell culture.

114. A method for producing a ~~VEGF-3~~ polypeptide, comprising:

(a) culturing the genetically engineered host cell of claim 109 under conditions suitable to produce the polypeptide; and

(b) recovering the polypeptide from the cell culture.

115. A method for producing a ~~VEGF-3~~ polypeptide, comprising:

(a) culturing the genetically engineered host cell of claim 110 under conditions suitable to produce the polypeptide; and

(b) recovering the polypeptide from the cell culture.

116. A method for producing a VEGF-3 polypeptide, comprising:

(a) culturing the genetically engineered host cell of claim 111 under conditions suitable to produce the polypeptide; and

(b) recovering the polypeptide from the cell culture.

117. A pharmaceutical composition comprising the isolated nucleic acid molecule of claim 74 in a pharmaceutically acceptable carrier.

118. A pharmaceutical composition comprising the isolated nucleic acid molecule of claim 75 in a pharmaceutically acceptable carrier.

119. A pharmaceutical composition comprising the isolated nucleic acid molecule of claim 76 in a pharmaceutically acceptable carrier.

120. A pharmaceutical composition comprising the isolated nucleic acid molecule of claim 77 in a pharmaceutically acceptable carrier.

121. A pharmaceutical composition comprising the isolated nucleic acid molecule of claim 78 in a pharmaceutically acceptable carrier.

122. An isolated nucleic acid molecule comprising a polynucleotide selected from the group consisting of:

(a) a polynucleotide encoding a polypeptide fragment of SEQ ID NO:2, wherein said polypeptide fragment comprises at least 50 amino acids of SEQ ID NO:2, and wherein said polypeptide fragment binds an antibody having specificity for the polypeptide of SEQ ID NO:2;

(b) a polynucleotide encoding a polypeptide fragment of at least 50 amino acids encoded by the cDNA contained in ATCC Deposit No. 97116, wherein said polypeptide fragment binds an antibody having specificity for the polypeptide of SEQ ID NO:2;

(c) a polynucleotide encoding a polypeptide fragment of SEQ ID NO:2, wherein said polypeptide fragment comprises at least 50 amino acids of SEQ ID NO:2, and wherein said polypeptide fragment has angiogenic activity; and

(d) a polynucleotide encoding a polypeptide fragment of at least 50 amino acids encoded by the cDNA contained in ATCC Deposit No. 97116, wherein said polypeptide fragment has angiogenic activity.

123. The isolated nucleic acid molecule of claim 122, wherein said polynucleotide is (a).

124. The isolated nucleic acid molecule of claim 122, wherein said polynucleotide is (b).

125. The isolated nucleic acid molecule of claim 122, wherein said polynucleotide is (c).

126. The isolated nucleic acid molecule of claim 122, wherein said polynucleotide is (d).

127. The isolated nucleic acid molecule of claim 122, wherein said polynucleotide is fused to a heterologous polynucleotide.

128. The isolated nucleic acid molecule of claim 127, wherein said heterologous polynucleotide encodes a heterologous polypeptide.

129. A recombinant vector comprising the isolated nucleic acid molecule of claim 122.

130. The recombinant vector of claim 129, wherein said isolated nucleic acid molecule is operatively associated with a regulatory sequence that controls gene expression.

131. A genetically engineered host cell comprising the isolated nucleic acid molecule of claim 122.

132. The genetically engineered host cell of claim 131, wherein said polynucleotide is operatively associated with a regulatory sequence that controls gene expression.

133. A method for producing a ~~VEGF-3~~ polypeptide, comprising:

(a) culturing the genetically engineered host cell of claim 132 under conditions suitable to produce the polypeptide; and

(b) recovering the polypeptide from the cell culture.

134. A pharmaceutical composition comprising the isolated nucleic acid molecule of claim 122 in a pharmaceutically acceptable carrier.

135. An isolated nucleic acid molecule comprising a polynucleotide which encodes 50 contiguous amino acids of SEQ ID NO:2.--